Relationship between C-reactive protein and antipsychotics levels in schizophrenic patients infected with COVID-19.

In the context of the COVID-19, inflammation emerges as a prominent characteristic. C-reactive protein (CRP) serves as a commonly employed marker for the evaluation of inflammation. This study aimed to examine the correlation between CRP levels and antipsychotic drug concentrations in patients diagnosed with SCZ during the COVID-19 pandemic. A total of 186 SCZ patients were included in this study, which utilized electronic medical records. The collected data encompassed SCZ diagnoses based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, respiratory symptoms, and treatments. Laboratory assessments involved the measurement of CRP levels and monitoring of blood drug concentrations. The most prevalent symptoms observed in the patient cohort were fever (59.14%), cough (52.15%), fatigue (45.7%), sore throat (46.24%), runny nose (28.49%), and stuffy nose (25.27%). The levels of CRP during the infection period were significantly higher compared to both the prophase and anaphase of infection (all p < 0.001). The serum levels of clozapine, olanzapine, aripiprazole, quetiapine, and risperidone were elevated during the infection period (all p < 0.001). During the anaphase of infection, patients exhibited higher serum levels of clozapine, olanzapine, and risperidone (all p < 0.001) compared to the infection period, but there was no significant change in serum levels of aripiprazole and quetiapine. Multiple regression analysis revealed a statistically significant positive correlation (P < 0.0001) between CRP and clozapine concentration. In light of the COVID-19 pandemic, it is crucial to adjust the dosage based on drug serum concentration to prevent intoxication or adverse drug reactions.

Cold atmospheric plasma (CAP)-modified and bioactive protein-loaded core-shell nanofibers for bone tissue engineering applications.

Coaxial electrospinning is a novel technique for producing core-shell nanofibers that provide a robust structure and deliver hydrophilic bioactive agents. Optimization of parameters used in the coaxial electrospinning process allows for the fabrication of uniform and bead-free polyvinyl alcohol (PVA)/poly (l-lactic acid) (PLLA) core-shell nanofibers. Herein, a cold atmospheric plasma (CAP) process was used to enhance the surface features of electrospun core-shell nanofibers for increased surface pore size and altered surface hydrophilicity. After CAP treatment, the scaffolds' water contact angle was reduced from 110° to 50° and its protein and water adsorption were significantly elevated. The changes in hydrophilicity and improved scaffold surface area dramatically enhanced cell attachment and proliferation of fibroblasts and osteoblasts. Also, the increased levels of alkaline phosphatase (ALP) activity, total protein content and calcium deposition from mesenchymal stem cells (MSCs) indicated a higher osteoinductivity of the CAP-modified nanofibrous scaffold. Most importantly, the increased nanofiber surface pore size induced by the CAP treatment further contributed to significant variations in drug release profiles. The CAP-treated scaffolds showed more rapid release kinetics compared to untreated scaffolds, which eventually led to complete drug release. These results indicated that the CAP-treated and bioactive protein-loaded core-shell nanofibers could be a valuable regenerative medicine and drug delivery system for improved bone tissue engineering.